[ 68 Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker
American Journal of Neuroradiology · 2026-09 · 47 (9) · 2342-2347
DOI: 10.3174/ajnr.a9260 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Neuroradiology, online erschienen am 23.02.2026. Verfasst von Kellen Vo Vu und 17 weiteren Autor:innen. Beteiligte Einrichtung: From the MD Program (K.V.V., H.G.O.), Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Bevacizumab, Meningeal Neoplasms, Meningioma, Organometallic Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the MD Program (K.V.V., H.G.O.), Weill Cornell Medicine, New York, New York.
- Department of Radiation Oncology (A.B., K.B., J.P.S.K.), Weill Cornell Medicine, New York, New York.
- Department of Diagnostic Radiology (J.R.O., A.H., S.H.K., J.I.), Weill Cornell Medicine, New York, New York.
- Department of Neurological Surgery (P.E.S., R.R.R., K.R.), Weill Cornell Medicine, New York, New York.
- Department of Pathology (B.L.), Weill Cornell Medicine, New York, New York.
- Hackensack Meridian Health (S.C.P.), West Orange, New Jersey.
ORCID-Profile: Kellen Vo Vu, Joseph R Osborne, Philip E Stieg, Rohan R Ramakrishna, Arsalan Haghdel, Sean H Kim, Jonathan P S Knisely, Rajiv S Magge, Peter C Pan, Jana Ivanidze
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Vu, K. V., Otis, H. G., Brandmaier, A., Osborne, J. R., Stieg, P. E., Ramakrishna, R. R., Haghdel, A., Kim, S. H., Liechty, B., Rosen, K., Beal, K., Pannullo, S. C., Knisely, J. P. S., Magge, R. S., Welch, M., Iwamoto, F., Pan, P. C., & Ivanidze, J. (2026). [ 68 Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker. American Journal of Neuroradiology, 47(9), 2342-2347. https://doi.org/10.3174/ajnr.a9260
Vancouver
Vu KV, Otis HG, Brandmaier A, Osborne JR, Stieg PE, Ramakrishna RR, et al. [ 68 Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker. American Journal of Neuroradiology. 2026;47(9):2342-2347. doi:10.3174/ajnr.a9260
BibTeX
@article{Vu2026,
author = {Vu, Kellen Vo and Otis, Hannah G and Brandmaier, Andrew and Osborne, Joseph R and Stieg, Philip E and Ramakrishna, Rohan R and Haghdel, Arsalan and Kim, Sean H and Liechty, Benjamin and Rosen, Kate and Beal, Kathryn and Pannullo, Susan C and Knisely, Jonathan P S and Magge, Rajiv S and Welch, Mary and Iwamoto, Fabio and Pan, Peter C and Ivanidze, Jana},
title = {[ 68 Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker},
journal = {American Journal of Neuroradiology},
year = {2026},
volume = {47},
number = {9},
pages = {2342--2347},
doi = {10.3174/ajnr.a9260}
}
EUVIMED